Cost and coverage: questions and answers

Zepbound's list price was about $1,086 per 4-week supply of pens as of mid-2026, but most self-pay patients pay less through LillyDirect vials. Lilly listed self-pay vials at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg.

Prices change often, so check the current price on Lilly's site or with your pharmacy before you fill. Compare options on the Zepbound savings page.

Wegovy's list price was about $1,349 per 4-week supply as of mid-2026. Through NovoCare Pharmacy self-pay, Novo Nordisk listed all doses at $349 a month, with an introductory $199 offer for new self-pay patients' first fills.

Offers and eligibility change, so check the current price on Novo Nordisk's site before filling. Your total yearly cost depends on dose and how long you stay on it. Estimate it with the GLP-1 cost calculator.

Ozempic's list price was about $998 per pen, roughly a 4-week supply, as of mid-2026. Novo Nordisk's NovoCare Pharmacy self-pay program listed most doses at $349 and the 2 mg dose at $499.

Ozempic is approved for type 2 diabetes, and most insurance plans cover it for that use, often with prior authorization. Check the current price before filling, since programs change. See Ozempic savings.

The Wegovy pill launched in January 2026 with self-pay pricing. As of mid-2026, Novo Nordisk listed the 1.5 mg and 4 mg tablets at $149 a month and the 9 mg and 25 mg tablets at $299 a month for self-pay.

Commercial insurance savings offers may also apply. Pricing is new and can change, so check the current price with Novo Nordisk or your pharmacy. See Wegovy pill savings.

It depends on your dose, insurance and pharmacy. For self-pay, generic liraglutide and the lower-dose Wegovy pill tablets are often among the lowest-cost options, while manufacturer self-pay programs for Zepbound vials and Wegovy have narrowed the gap.

Price is not the only factor. Liraglutide is a daily shot with smaller average weight loss. Compare current prices side by side in our GLP-1 cost index, then confirm with your pharmacy.

Lilly's Zepbound savings card can bring the cost down to as low as $25 per fill for eligible people with commercial insurance that covers Zepbound. Monthly and yearly caps and other terms apply.

You usually activate the card online and give it to your pharmacy with your insurance. It cannot be used with Medicare, Medicaid or other government insurance. Check current terms on Lilly's site. See Zepbound savings.

Yes. Novo Nordisk offers a Wegovy savings offer for eligible people with commercial insurance that covers Wegovy. It lowers your copay up to a maximum benefit, which changes over time.

It does not apply to Medicare, Medicaid or other government plans, and it does not help if your plan excludes Wegovy. In that case, the NovoCare self-pay price may be the better route. Check current terms on Novo Nordisk's site. See Wegovy savings.

No. Manufacturer copay savings cards cannot be used with Medicare, Medicaid, TRICARE or other government health plans because of federal rules on drug company payments.

Medicare enrollees can still look at Part D coverage for approved uses, Extra Help if they qualify, state assistance programs and manufacturer patient assistance programs. Some choose self-pay pricing outside their plan. Ask your pharmacist how a self-pay purchase interacts with your Part D plan.

LillyDirect is Eli Lilly's direct-to-patient pharmacy service. It sells Zepbound single-dose vials at self-pay prices, which as of mid-2026 were listed at $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg per month.

You need a valid prescription. Vials require a syringe and needle, so ask a pharmacist to show you how to draw up a dose. Check the current price and terms on Lilly's site before ordering.

NovoCare Pharmacy is Novo Nordisk's self-pay pharmacy program for Wegovy and Ozempic. As of mid-2026, it listed Wegovy at $349 a month for all doses, with a $199 introductory offer for new self-pay patients, and Ozempic at $349 for most doses.

You need a valid prescription, and these purchases usually do not count toward insurance deductibles. Check the current price and eligibility on Novo Nordisk's site before ordering.

Sometimes. Many employer plans exclude weight-loss medicines entirely, so check your formulary first. When they are covered, plans usually require prior authorization with a recorded BMI and weight-related conditions.

Coverage for type 2 diabetes is much more common. Call the number on your insurance card and ask whether Zepbound or Wegovy is on the formulary and what the criteria are. See Zepbound insurance coverage for questions to ask.

Coverage follows the approved use, not the ingredient. Ozempic is approved for type 2 diabetes, which most plans cover, while Wegovy is approved for weight management, which many plans exclude.

Plans may deny Ozempic without a diabetes diagnosis and may audit for off-label weight-loss use. If you have heart disease, Wegovy's heart-risk indication may change your coverage options. Ask your plan which uses it covers. See Wegovy insurance.

Medicare Part D cannot cover drugs used only for weight loss under the law that created the program. But Part D plans can cover Wegovy for an approved use such as reducing heart-attack and stroke risk in adults with heart disease and obesity or overweight.

A temporary CMS program, the Medicare GLP-1 Bridge, also began July 1, 2026 for some enrollees. Check Medicare.gov or your plan for current rules. See Medicare and GLP-1s.

Medicare Part D plans can cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, because that is an FDA-approved use rather than weight loss alone. Plans usually require prior authorization and proof of the diagnosis, such as a sleep study.

Coverage, tiers and costs vary by plan, so call your Part D plan or check its formulary. Our guide to GLP-1s and sleep apnea has more.

The Medicare GLP-1 Bridge is a temporary CMS program running from July 1, 2026 through December 31, 2027. It covers certain weight-management GLP-1s, including Wegovy, for eligible Part D enrollees who meet prior authorization criteria, with a reported flat copay of about $50 a month.

People who already get a GLP-1 through Part D for another covered condition, such as diabetes, follow standard Part D rules instead. Check CMS.gov or Medicare.gov for current criteria.

It depends on your state. Medicaid programs must generally cover GLP-1s for type 2 diabetes, but coverage for weight management is optional, and states decide for themselves. Several states have added or dropped obesity coverage in recent years.

Call your state Medicaid office or your managed care plan to ask about current rules and prior authorization criteria. Our guide to Medicaid GLP-1 coverage explains what to ask.

Prior authorization is approval your insurance plan requires before it pays for a medicine. For weight-management GLP-1s, plans usually want a recorded BMI, any weight-related conditions and sometimes proof that you tried a diet program.

Your prescriber's office submits the request. Renewals often require documented weight loss, commonly at least 5%, after the first 3 to 6 months. Read our step-by-step guide to GLP-1 prior authorization.

Many plans decide within a few days to two weeks once they have everything they need, and expedited reviews for urgent cases are faster. Missing paperwork is the most common cause of delay.

Ask your prescriber's office when the request was sent, and call your plan to confirm it arrived and whether anything is missing. Ask whether the approval has an end date, so you can plan the renewal before it lapses.

Read the denial letter to find the exact reason, then ask your prescriber whether to resubmit with missing details or file an appeal. Common fixes include adding BMI records, related diagnoses or proof of an earlier diet program.

Your prescriber can also request a peer-to-peer review with the plan's doctor. If you need a prescriber who can help with the paperwork, a clinician can reach out through find a clinician.

Start with an internal appeal through your plan, following the steps and deadline in your denial letter. Under the Affordable Care Act, most plans give you 180 days to file. Include a letter of medical necessity from your prescriber and supporting records.

If the internal appeal fails, you can usually request an external review by an independent reviewer. Keep copies of everything and note who you spoke with and when. HealthCare.gov explains the process.

Many plans approve weight-management GLP-1s for a limited time, then require proof that the medicine is working. Renewals often ask for documented weight loss, commonly at least 5%, after the first 3 to 6 months.

Plans also change formularies at the start of a new plan year. Ask your plan what it needs, and ask your prescriber to send updated weight records. If your plan dropped the drug, ask about a formulary exception or a covered alternative.

Step therapy means your plan requires you to try a lower-cost or preferred medicine first before it covers the one your prescriber chose. For diabetes, plans may require metformin or a preferred GLP-1 brand first.

If you already tried the required drug, or it is not safe for you, your prescriber can request a step therapy exception with documentation. Ask your plan for its written criteria so you know exactly what it needs.

Usually yes. Prescription medicines used to treat a medical condition, including obesity diagnosed by a clinician, are generally eligible medical expenses under IRS rules, so HSA and FSA funds can typically be used for them.

Keep your prescription and receipts, and check with your plan administrator, since some ask for a letter of medical necessity. Our guide to HSA, FSA and GLP-1s covers the details.

The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in December 2024. Once its grace periods ended in 2025, pharmacies could no longer routinely make copies of these drugs under shortage rules.

Compounding is still allowed in narrow cases, such as a documented medical need for a change from the approved product. Compounded versions are not FDA approved. See our guide to compounded GLP-1s.

The FDA says compounded GLP-1 drugs are not FDA approved and do not go through FDA review for safety, effectiveness or quality before they are sold. It has received adverse event reports, some needing hospitalization, linked to dosing errors with compounded semaglutide.

The FDA has also sent warning letters to sellers that described compounded products as FDA approved or the same as brand drugs. Talk with your prescriber before using one. See compounded semaglutide.

No. Compounded tirzepatide is not the same as Zepbound or Mounjaro. It is not FDA approved, its quality and strength are not checked by the FDA, and it may come in different concentrations, which raises the risk of dosing errors.

Brand Zepbound is made under FDA manufacturing standards and studied in large trials. If cost is the issue, compare manufacturer self-pay prices first. More on compounded tirzepatide.

Semaglutide sodium and semaglutide acetate are salt forms some compounders have used. The FDA has said these salt forms are different active ingredients from the semaglutide in approved products, and it is not aware of any basis for compounding with them.

Products made from salt forms have no FDA review for safety or effectiveness. If a pharmacy or online seller offers one, ask your prescriber and pharmacist what exactly is in the vial before you use it.

Only through a licensed US pharmacy with a valid prescription. The FDA has warned about counterfeit Ozempic and about websites selling GLP-1s without a prescription, which may contain the wrong ingredient, wrong dose or contaminants.

Warning signs include no prescription required, prices far below self-pay programs and "research use only" labels. Check that an online pharmacy is licensed in your state. If a product looks different from what you usually get, ask your pharmacist before using it.

The list price is the manufacturer's starting price before insurance, rebates or discounts. What you pay depends on your plan's deductible, coinsurance or copay tier, any savings card and the pharmacy you use.

Coinsurance is a percentage of the price, so it can be high before you meet your deductible. Ask your plan for your exact cost at an in-network pharmacy, and compare it with manufacturer self-pay prices. Our GLP-1 cost calculator helps compare.

Start by checking whether your plan covers a GLP-1 for a condition you have, such as diabetes, heart disease or sleep apnea. Then compare the copay with a savings card against manufacturer self-pay prices.

Other options include asking about a lower-cost covered alternative, using HSA or FSA funds, a 90-day supply if your plan allows it and patient assistance programs. Price comparisons are in our GLP-1 cost index. Check current prices before filling.